2024.10.24KisoJi Biotechnology, one of Remiges' portfolio companies, has entered a strategic collaboration agreement with Cancer Research UK on KisoJi's unique single-domain antibody program, KJ-103 targeting TROP2 for the treatment of solid tumors

2024.10.08Qinotto, one of Remiges' portfolio companies, has entered a research collaboration and license agreement with Lilly on a novel shuttle program for delivering novel agents beyond blood-brain barrier for the treatment of neurodegenerative diseases

2024.09.26OMEICOS, a portfolio company of Remiges Ventures, completes enrollment of PMD-OPTION study in primary mitochondrial disease

2024.09.10LUCA Science, a portfolio company of Remiges Ventures, has published significant research findings in Nature Metabolism: The study highlights how mitochondria transfer-based therapies can reduce morbidity and mortality in Leigh syndrome

2024.05.10ENB Therapeutics, one of Remiges Ventures’ portfolio companies, announced clinical collaboration between Coherus and the Cancer Research Institutes using ENB-003 for the treatment of ovarian cancer

　　News　＞　

What Remiges Does >

Team >

Portfolio Companies >

Contact >

LP Portal >